Nohaile Michael 4
4 · Fulgent Genetics, Inc. · Filed May 18, 2026
Research Summary
AI-generated summary of this filing
Fulgent Genetics Director Michael Nohaile Receives Equity Awards
What Happened Michael Nohaile, a director of Fulgent Genetics, was granted equity awards on May 14, 2026: 5,558 restricted stock units (RSUs) and 8,426 derivative shares (awarded as a derivative/security). Both grants were recorded at $0.00 per share (no cash paid at grant). These are awards (compensation), not open-market purchases or sales.
Key Details
- Transaction date: 2026-05-14; filed with SEC on 2026-05-18 (within the typical 2-business-day reporting window).
- Grant details: 5,558 shares (RSUs) and 8,426 derivative shares; price reported $0.00; total reported value $0.
- Shares owned after transaction: not specified in the provided filing details.
- Footnotes/vesting:
- F1 (RSUs): Vest over 4 years — 1/4 vests 12 months after May 14, 2026, then 1/16th vests every 3 months over the next 36 months, subject to continued service.
- F2 (derivative/option): Vest schedule mirrors F1 (4 years total; 1/4 after 12 months; 1/16th every 3 months thereafter), subject to continued service.
- Transaction code: A = Grant/award/other acquisition (compensation).
Context These awards are typical compensation grants to align executive/director incentives with shareholder interests; they are not purchases or sales. The derivative award vests on a schedule (not immediately exercisable/salable); there is no indication of a cashless exercise or immediate sale in this filing. For retail investors, granted awards signal compensation decisions but are not direct market bets by the insider.
Insider Transaction Report
- Award
Common Stock
[F1]2026-05-14+5,558→ 24,578 total - Award
Stock Option (Right to Buy)
[F2]2026-05-14+8,426→ 8,426 totalExercise: $16.19Exp: 2036-05-13→ Common Stock (8,426 underlying)
Footnotes (2)
- [F1]Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date.
- [F2]The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date.